Roth MKM Initiates Coverage On Reviva Pharmaceuticals with Buy Rating, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Scott Henry has initiated coverage on Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy rating and a price target of $12.
September 20, 2023 | 9:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reviva Pharmaceuticals has been initiated with a Buy rating by Roth MKM, with a price target of $12.
The initiation of coverage by Roth MKM with a Buy rating is a positive signal for Reviva Pharmaceuticals. The price target of $12 suggests that the analyst sees significant upside potential in the stock. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100